Welcome to our dedicated page for Bicycle Therapeutics news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics stock.
Bicycle Therapeutics plc develops clinical-stage medicines based on its proprietary bicyclic peptide, or Bicycle®, technology. Its updates center on oncology programs using fully synthetic constrained peptides, including nuzefatide pevedotin, a Bicycle Drug Conjugate targeting EphA2; zelenectide pevedotin, a Bicycle Drug Conjugate targeting Nectin-4; BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist targeting Nectin-4 and CD137; and Bicycle Radioconjugates for radiopharmaceutical use.
Recurring news includes clinical and preclinical data presentations, oncology pipeline updates, financial results, leadership changes, and collaborations that support radioisotope and radiopharmaceutical supply. Company announcements also discuss work with partners in additional therapeutic areas and the structure of its U.K. and U.S. operations.
Bicycle Therapeutics (NASDAQ: BCYC) announced that Genentech, part of the Roche Group, has exercised its second expansion option under a 2020 collaboration agreement, initiating a new program to develop Bicycle®-based immuno-oncology therapies. This move entails a $10 million payment to Bicycle, marking significant progress in their strategic partnership. The collaboration focuses on discovering and pre-clinically developing novel therapeutics targeting multiple cancer types. Both companies are optimistic about the potential of Bicycle technology in advancing cancer treatment.
Bicycle Therapeutics (NASDAQ: BCYC) announced the dosing of the first patient in the Phase I/II trial of BT5528, a second-generation Bicycle Toxin Conjugate designed to target EphA2. Following a successful Phase I dose escalation, the expansion phase aims to evaluate BT5528's clinical activity in various cancer types, administering a recommended Phase II dose of 6.5 mg/m2 biweekly. Initial data, including safety and anti-tumor activity, is anticipated to be released next quarter. The trial includes up to 56 patients in the initial cohorts.
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology firm focused on a unique class of therapeutics, will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on June 8, 2022, at 8:00 a.m. ET. Investors can access a live webcast on their official site, with an archived replay available for 90 days post-event. Bicycle is pioneering the development of 'Bicycles,' synthetic short peptides that offer high affinity and selectivity for targeted diseases. Current clinical trials include BT5528 and BT8009, targeting EphA2 and Nectin-4.
Bicycle Therapeutics (NASDAQ: BCYC) announced the presentation of a Trials in Progress poster for its Phase I/II clinical trial of BT7480 at the 2022 ASCO Annual Meeting in Chicago, IL, scheduled for June 5, 2022. BT7480 is a novel Bicycle TICA™ targeting Nectin-4 while agonizing CD137 in patients with advanced malignancies. The study aims to evaluate the therapeutic potential of BT7480 in addressing unmet medical needs in oncology. Additional details about the study will be available on their website following the presentation.
Summary not available.
Bicycle Therapeutics (NASDAQ: BCYC) reported significant clinical progress in its oncology pipeline during Q1 2022, including promising interim data for the BT8009 Phase I clinical trial with a 50% overall response rate in patients with urothelial cancer. As of March 31, 2022, the company has $407.4 million in cash and equivalents, expected to fund operations through 2024. However, it reported a net loss of $27.6 million, or $(0.93) per share, compared to a loss of $16.2 million in Q1 2021.
Egle Therapeutics SAS has appointed Pierre Legault as Chairman and board member, effective March 2022. With over 35 years of experience in the biotech sector, his leadership is anticipated to enhance Egle's efforts in developing novel immunotherapies targeting regulatory T cells (Tregs) for oncology and autoimmune diseases. Mr. Legault's previous roles include Director at Syndax Pharmaceuticals and Chairman at Bicycle Therapeutics (BCYC), positioning him well to accelerate Egle's strategic initiatives.
Bicycle Therapeutics (NASDAQ: BCYC) announced interim Phase I results for BT8009, a second-generation BTC targeting Nectin-4, at the 2022 AACR Annual Meeting. The overall confirmed response rate was 50%, with one complete response among eight urothelial cancer patients at a 5.0mg/m² dosage. No dose-limiting toxicities were observed, and the tolerability profile remained favorable. Four of five responders are still on therapy after 24 weeks. The Phase I trial continues to explore additional dosing options. A conference call will provide further insights.
Bicycle Therapeutics (NASDAQ: BCYC) announced the presentation of interim Phase I results for BT8009, targeting Nectin-4, at the 2022 American Association for Cancer Research Annual Meeting. The oral presentation titled BT8009-100 Phase I/II Study will be on April 10, 2022, at 4:05 PM CT, presented by Meredith McKean from the Sarah Cannon Research Institute. Following the presentation, the company will hold a conference call on April 11, 2022, at 8:30 AM ET to discuss the findings.
Bicycle Therapeutics (NASDAQ: BCYC) announced updated preclinical results demonstrating the efficacy of its Bicycle® technology as a novel antiviral therapy against SARS-CoV-2. Presented at the 2022 Microbiology Society Annual Meeting in Dublin, the data showed that Bicycles bind to various epitopes of the SARS-CoV-2 spike protein and exhibit potent activity in vitro and in vivo. The research has received funding from InnovateUK, and Bicycle is optimistic about the potential of these small molecules in combating COVID-19 variants.